RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
RBC Capital has maintained its Outperform rating for Agios Pharmaceuticals (NASDAQ:AGIO) and increased its price target from $40.00 to $42.00. Agios Pharmaceuticals' shares are trading up 0.93% over the last 24 hours, at $27.73 per share. A move to $42.00 would account for a 51.49% increase from the current share price.
June 27, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained its Outperform rating for Agios Pharmaceuticals and raised its price target, indicating a positive outlook for the company.
The maintained Outperform rating and increased price target by RBC Capital indicates a positive outlook for Agios Pharmaceuticals. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100